The benefits of diagnostic innovation rely on appropriate clinical practice reforms. The development of troponin T and I assays for assessing and managing patients with chest pain has revolutionised care for those with suspected or confirmed acute coronary syndromes. The availability of these assays has led to more patients who are at increased risk of recurrent cardiac events being identified, plus improvements in selecting patients who might benefit from early invasive management and revascularisation and more potent antithrombotic therapy. Development of point‐of‐care testing has extended the reach of these assays to inform the care of patients presenting in rural and remote areas of Australia.
|Number of pages||2|
|Journal||Medical Journal of Australia|
|Publication status||Published - 4 Aug 2014|